(Q35595076)

English

Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines

scientific article published on October 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

author name string

R A J Ransford

1

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

M J S Langman

2

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

language of work or name

0 references

publication date

1 October 2002

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

51

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

536-539

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Ulcer complications associated with anti-inflammatory drug use. What is the extent of the disease burden?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773410

12 July 2018

Direct toxicity of nonsteroidal antiinflammatory drugs for renal medullary cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773410

12 July 2018

Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773410

12 July 2018

Successfully treated sulphasalazine-induced fulminant hepatic failure, thrombocytopenia and erythroid hypoplasia with intravenous immunoglobulin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773410

12 July 2018

Renal and urologic complications of inflammatory bowel disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773410

12 July 2018

Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773410

12 July 2018

Adverse events in patients treated with 5-aminosalicyclic acid: 1993-1994 pharmacovigilance report for Pentasa in France

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773410

12 July 2018

Mesalazine-associated interstitial nephritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773410

12 July 2018

Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773410

12 July 2018

Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773410

12 July 2018

Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773410

12 July 2018

Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773410

12 July 2018

Hypersensitivity with hepatotoxicity to mesalazine after hypersensitivity to sulfasalazine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773410

12 July 2018

An experiment to determine the active therapeutic moiety of sulphasalazine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773410

12 July 2018

Hypersensitivity to salicylazosulfapyridine: renal and hepatic toxic reactions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773410

12 July 2018

Mesalazine induced interstitial nephritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773410

26 September 2018

Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773410

15 November 2018

Non-steroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions--2

1 reference

https://pubmed.ncbi.nlm.nih.gov/12235076

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine

1 reference

https://pubmed.ncbi.nlm.nih.gov/12235076

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sulfasalazine associated agranulocytosis in Sweden 1972-1989. Clinical features, and estimation of its incidence

1 reference

https://pubmed.ncbi.nlm.nih.gov/12235076

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The risk of sulfasalazine- and mesalazine-associated blood disorders

1 reference

https://pubmed.ncbi.nlm.nih.gov/12235076

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/12235076

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intention-to-treat analysis of 200 patients with rheumatoid arthritis 12 years after random allocation to either sulfasalazine or penicillamine

1 reference

https://pubmed.ncbi.nlm.nih.gov/12235076

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/GUT.51.4.536

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35595076&oldid=2050652169"